Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease

Abstract

Background: The effect of low-frequency functional variation on anti-tumor necrosis factor alpha (TNF) response in Crohn’s disease (CD) patients remains unexplored. The objective of this study was to investigate the impact of functional rare variants in clinical response to anti-TNF therapy in CD. Methods: CD anti-TNF naïve patients starting anti-TNF treatment due to active disease [Crohn’s Disease Activity Index (CDAI > 150)] were included. The whole genome was sequenced using the Illumina Hiseq4000 platform. Clinical response was defined as a CDAI score <150 at week 14 of anti-TNF treatment. Low-frequency variants were annotated and classified according to their damaging potential. The whole genome of CD patients was screened to identify homozygous loss-of-function (LoF) variants. The TNF signaling pathway was tested for overabundance of damaging variants using the SKAT-O method. Functional implication of the associated rare variation was evaluated using cell-type epigenetic enrichment analyses. Results: A total of 41 consecutive CD patients were included; 3250 functional rare variants were identified (2682 damaging and 568 LoF variants). Two homozygous LoF mutations were found in HLA-B and HLA-DRB1 genes associated with lack of response and remission, respectively. Genome-wide LoF variants were enriched in epigenetic marks specific for the gastrointestinal tissue (colon, p = 4.11e–4; duodenum, p = 0.011). The burden of damaging variation in the TNF signaling pathway was associated with response to anti-TNF therapy ( p = 0.016); damaging variants were enriched in epigenetic marks from CD8+ ( p = 6.01e–4) and CD4+ ( p = 0.032) T cells. Conclusions: Functional rare variants are involved in the response to anti-TNF therapy in CD. Cell-type enrichment analysis suggests that the gut mucosa and CD8+ T cells are the main mediators of this response.

Exploring Pharmacogenetic Factors Influencing Hydroxyurea Response in Tanzanian Sickle Cell Disease Patients: A Genomic Medicine Approach

“…Studies have revealed that rare pharmacogenetic variants are strongly enriched in mutations predicted to cause functional alterations, and they significantly contribute to the inter-individual variability in drug response. For example, rare genetic variants have been found to influence the clinical response to anti-TNF therapy, with low-frequency loss-of-function variants being associated with the therapy's response [70] .…”

Human leukocyte antigens in inflammatory bowel disease

“…A study carried out in our setting sequenced the entire genome of 41 patients with CD without previous anti-TNF treatment in search of variants related to response to treatment. Two homozygous mutations were identified in HLA-B (variant rs41563412) and HLA-DRB1 (variant rs1071752) associated with non-response and remission, respectively, at week 14 27 .…”

Effects of Golimumab and Ustekinumab on Circulating Dendritic Cell Migratory Capacity in Inflammatory Bowel Disease

“…However, only 30% of the patients achieve this therapeutic objective [16]. Furthermore, the medical community does not have criteria for selecting beneficial drugs for specific patients [17]. Following the failure of medical treatments, patients often resort to surgery, which can lead to both physical and social burdens.…”